Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 4655
Sealed predictions
- CCDC85C in dopamine neurons, braak-0.35 (p 0.358) → -0.41 (p 0.276)receipt 4663
Swarm cases
receipt 4663: CCDC85C in dopamine neurons, braak
- power
- full sample -0.41 (p 0.089, n 18), 95% CI -0.74 to +0.07. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.41 (p 0.089, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.52 (p 0.027, n 18). not the mix.
- skeptic
- leave-one-out range -0.58 to -0.34, sign flips 0; without severely affected donors -0.41 (p 0.089, n 18). robust.
- cell type
- strongest in oligodendrocytes: -0.71 (p 0.0011, n 18) vs -0.41 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CCDC85C in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CCDC85C · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.43 p 0.131 (needs p < 4.3e-4)
Receipts
loading the receipts